Shenzhen Biopharmaceutical Company Receives $15 Million U.S. Venture Capital

China's leading pharmaceutical biopharmaceutical company, Shenzhen Hanyu Pharmaceutical Co., Ltd. has reached an agreement with Softbank Safari Asia Investment and Shenzhen Innovation Investment Co., Ltd., and has received a huge initial investment of US$15 million from the two venture capital giants.

In recent years, Shenzhen enterprises, which are in the leading position in the fields of biomedicine and medical devices, have received increasing attention from domestic and foreign venture capital industries and capital markets. This time, Shenzhen Hanyu got a huge investment from two major venture capitalists and achieved a breakthrough in the biopharmaceutical industry in Shenzhen and even in China.